We are a clinical-stage C lustered R egularly I nterspaced S hort P alindromic R epeats (“CRISPR”) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA ( C RISPR h ybrid R NA- DNA , or “chRDNA,” pronounced “chardonnay”) genome-editing technology, which enables more precise genome editing of allogeneic cell therapies.
Second-line large B-cell lymphoma (2L LBCL), transplant-ineligible(Phase 3)
Status note Lead program; ANTLER Phase 1 in r/r B-NHL ongoing. FDA alignment on pivotal Phase 3 ANTLER-3 design reached May 7, 2026 (~250 CD19-naive 2L LBCL patients, vispa-cel vs investigator's choice). RMAT (r/r LBCL), Fast Track (r/r B-NHL), Orphan (follicular lymphoma). No dated start/readout stated in this filing. Company discontinued preclinical research and two unnamed clinical programs (April 2025) with a ~32% workforce cut.
Status note CaMMouflage Phase 1 in 4L+ r/r MM; dose expansion (RDE 450x10^6 cells) initiated late 2025 and ongoing, enrolling BCMA-naive and BCMA-exposed cohorts. RMAT, Fast Track and Orphan Drug designations for r/r MM.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.